{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:47:55Z","timestamp":1780433275349,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T00:00:00Z","timestamp":1314748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s12325-011-0058-5","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T12:00:42Z","timestamp":1315310442000},"page":"748-760","source":"Crossref","is-referenced-by-count":9,"title":["Gouty arthritis: Understanding the disease state and management options in primary care"],"prefix":"10.1007","volume":"28","author":[{"given":"Prashanth","family":"Sunkureddi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,31]]},"reference":[{"key":"58_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-010-0092-3","volume":"12","author":"F. Martinon","year":"2010","unstructured":"Martinon F. Update on biology: uric acid and the activation of immune and inflammatory cells. Curr Rheumatol Rep. 2010;12:135\u2013141.","journal-title":"Curr Rheumatol Rep."},{"issue":"suppl.1","key":"58_CR2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G. Nuki","year":"2006","unstructured":"Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(suppl. 1):S1.","journal-title":"Arthritis Res Ther."},{"issue":"suppl.5","key":"58_CR3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3949\/ccjm.75.Suppl_5.S5","volume":"75","author":"B.F. Mandell","year":"2008","unstructured":"Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75(suppl. 5):S5\u2013S8.","journal-title":"Cleve Clin J Med."},{"key":"58_CR4","first-page":"801","volume":"76","author":"A.T. Eggebeen","year":"2007","unstructured":"Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76:801\u2013808.","journal-title":"Am Fam Physician."},{"issue":"suppl.6","key":"58_CR5","first-page":"S1","volume":"59","author":"M.A. Becker","year":"2010","unstructured":"Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(suppl. 6):S1\u2013S8.","journal-title":"J Fam Pract"},{"key":"58_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.amjmed.2006.02.044","volume":"120","author":"M.P. Keith","year":"2007","unstructured":"Keith MP, Gilliland WR. Updates in the management of gout. Am J Med. 2007;120:221\u2013224.","journal-title":"Am J Med."},{"key":"58_CR7","first-page":"S901","volume":"62","author":"Y. Zhu","year":"2010","unstructured":"Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: The National Health and Nutrition Examination Survey (NHANES). Arthritis Rheum. 2010;62:S901\u2013S902.","journal-title":"Arthritis Rheum."},{"issue":"suppl.1","key":"58_CR8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1907","volume":"8","author":"K.G. Saag","year":"2006","unstructured":"Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl. 1):S2.","journal-title":"Arthritis Res Ther."},{"key":"58_CR9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","volume":"48","author":"S.J. Lee","year":"2009","unstructured":"Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48:582\u2013586.","journal-title":"Rheumatology (Oxford)"},{"key":"58_CR10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"H.K. Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894\u2013900.","journal-title":"Circulation."},{"key":"58_CR11","first-page":"499","volume":"11","author":"J.B. Mapa","year":"2010","unstructured":"Mapa JB, Pillinger MH. New treatments for gout. Curr Opin Investig Drugs. 2010;11:499\u2013506.","journal-title":"Curr Opin Investig Drugs."},{"key":"58_CR12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F. Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u2013241.","journal-title":"Nature."},{"key":"58_CR13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301\u20131311.","journal-title":"Ann Rheum Dis"},{"key":"58_CR14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","volume":"170","author":"H.J. Janssens","year":"2010","unstructured":"Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van WC, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170:1120\u20131126.","journal-title":"Arch Intern Med."},{"issue":"suppl.5","key":"58_CR15","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3949\/ccjm.75.Suppl_5.S17","volume":"75","author":"R.K. Dore","year":"2008","unstructured":"Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75(suppl. 5):S17\u2013S21.","journal-title":"Cleve Clin J Med."},{"key":"58_CR16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"S.L. Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895\u2013900.","journal-title":"Arthritis Rheum."},{"key":"58_CR17","first-page":"1950","volume":"29","author":"W. Urano","year":"2002","unstructured":"Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29:1950\u20131953.","journal-title":"J Rheumatol."},{"key":"58_CR18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11926-010-0156-4","volume":"13","author":"R.G. Thiele","year":"2011","unstructured":"Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13:146\u2013153.","journal-title":"Curr Rheumatol Rep."},{"key":"58_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1756-185X.2009.01385.x","volume":"12","author":"M.C. Tolin","year":"2009","unstructured":"Tolin MC, Navarra SV. Severe hip and knee pain in a man with chronic tophaceous gout. Int J Rheum Dis. 2009;12:57\u201360.","journal-title":"Int J Rheum Dis."},{"key":"58_CR20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.bor.0000162060.25895.a5","volume":"17","author":"R.L. Wortmann","year":"2005","unstructured":"Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol. 2005;17:319\u2013324.","journal-title":"Curr Opin Rheumatol."},{"key":"58_CR21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","volume":"10","author":"G. Nuki","year":"2008","unstructured":"Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218\u2013227.","journal-title":"Curr Rheumatol Rep."},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312\u20131324.","journal-title":"Ann Rheum Dis"},{"key":"58_CR23","unstructured":"Celebrex(celecoxib capsules) [product information]. New York, NY: Pfizer Inc.; 2011."},{"key":"58_CR24","unstructured":"Napralen(naproxen sodium controlled-released tablets) [product information]. San Diego, CA: Victory Pharma, Inc.; 2011."},{"key":"58_CR25","unstructured":"Colcrys\u2122 (colchicine, USP tablets for oral use) [product information]. Corona, CA: Mutual Pharmaceutical Company, Inc.; 2009."},{"key":"58_CR26","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"R.A. Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060\u20131068.","journal-title":"Arthritis Rheum."},{"key":"58_CR27","unstructured":"Prednisone tablets USP [product information]. Columbus, OH: Roxane Labratories, Inc.; 2002."},{"key":"58_CR28","doi-asserted-by":"crossref","unstructured":"Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008:CD005521.","DOI":"10.1002\/14651858.CD005521.pub2"},{"issue":"suppl.5","key":"58_CR29","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.77.s2.01","volume":"77","author":"B.F. Mandell","year":"2010","unstructured":"Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. Cleve Clin J Med. 2010;77(suppl. 5). S2\u2013S25.","journal-title":"Cleve Clin J Med."},{"key":"58_CR30","first-page":"466","volume":"35","author":"L. Silva","year":"2010","unstructured":"Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatologica Portuguesa. 2010;35:466\u2013474.","journal-title":"Acta Reumatologica Portuguesa."},{"key":"58_CR31","unstructured":"ALLOPURINOL (allopurinol tablet) [product information]. Corona, CA: Watson Laboratories, Inc.; 2006."},{"key":"58_CR32","unstructured":"ULORIC\u00ae (Febuxostat tablet for oral use) [product information]. Deerfield, Ill: Takeda Pharmaceuticals America, Inc.; 2009."},{"key":"58_CR33","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"M.A. Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.","journal-title":"Arthritis Res Ther."},{"key":"58_CR34","unstructured":"PROBENECID [product information]. Corona, CA: Watson Pharmaceuticals Inc.; 2011."},{"key":"58_CR35","unstructured":"KRYSTEXXA\u2122 (pegloticase) Injection, for intravenous infusion [product information]. East Brunswick, NJ: Savient Pharmaceuticals, Inc.; 2010."},{"issue":"suppl.9","key":"58_CR36","first-page":"S176","volume":"58","author":"H.S. Baraf","year":"2008","unstructured":"Baraf HS, Becker MA, Edwards NL, et al. Tophus response to peloticase (PGL) therapy: pooled results of GOUT 1 and GOUT 2 PGL phase 3 randomized, doubleblind, placebo-controlled trials. Arthritis Rheum. 2008;58(suppl. 9):S176.","journal-title":"Arthritis Rheum."},{"key":"58_CR37","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A. So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.","journal-title":"Arthritis Res Ther."},{"key":"58_CR38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","volume":"40","author":"K. Chen","year":"2010","unstructured":"Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra\u2019s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210\u2013214.","journal-title":"Semin Arthritis Rheum"},{"key":"58_CR39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R. Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebocontrolled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613\u20131617.","journal-title":"Ann Rheum Dis."},{"key":"58_CR40","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A. So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064\u20133076.","journal-title":"Arthritis Rheum."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0058-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-011-0058-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-011-0058-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T20:53:45Z","timestamp":1560545625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-011-0058-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,31]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s12325-011-0058-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,31]]}}}